{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:34:10Z","timestamp":1789450450061,"version":"build-2803163510"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Goethe University Frankfurt"},{"name":"Idorsia Pharmaceuticals Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Treatment of patients with recent-onset type 1 diabetes with an anti-CD3 antibody leads to the transient stabilization of C-peptide levels in responder patients. Partial efficacy may be explained by the entry of islet-reactive T-cells spared by and\/or regenerated after the anti-CD3 therapy. The CXCR3\/CXCL10 axis has been proposed as a key player in the infiltration of autoreactive T cells into the pancreatic islets followed by the destruction of \u03b2 cells. Combining the blockade of this axis using ACT-777991, a novel small-molecule CXCR3 antagonist, with anti-CD3 treatment may prevent further infiltration and \u03b2-cell damage and thus, preserve insulin production.<\/jats:p>\n               <jats:p>The effect of anti-CD3 treatment on circulating T-cell subsets, including CXCR3 expression, in mice was evaluated by flow cytometry. Anti-CD3\/ACT-777991 combination treatment was assessed in the virally induced RIP-LCMV-GP and NOD diabetes mouse models. Treatments started at disease onset. The effects on remission rate, blood glucose concentrations, insulitis, and plasma C-peptide were evaluated for the combination treatment and the respective monotherapies.<\/jats:p>\n               <jats:p>Anti-CD3 treatment induced transient lymphopenia but spared circulating CXCR3+ T cells. Combination therapy in both mouse models synergistically and persistently reduced blood glucose concentrations, resulting in increased disease remission rates compared to each monotherapy. At the study end, mice in disease remission demonstrated reduced insulitis and detectable plasma C-peptide levels. When treatments were initiated in non-severely hyperglycemic NOD mice at diabetes onset, the combination treatment led to persistent disease remission in all mice.<\/jats:p>\n               <jats:p>These results provide preclinical validation and rationale to investigate the combination of ACT-777991 with anti-CD3 for the treatment of patients with recent-onset diabetes.<\/jats:p>","DOI":"10.1093\/cei\/uxad083","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T10:30:25Z","timestamp":1689589825000},"page":"131-143","source":"Crossref","is-referenced-by-count":15,"title":["Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetes"],"prefix":"10.1093","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-7976","authenticated-orcid":false,"given":"Urs","family":"Christen","sequence":"first","affiliation":[{"name":"Pharmazentrum Frankfurt, Goethe University Frankfurt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8727-1142","authenticated-orcid":false,"given":"Laetitia","family":"Pouzol","sequence":"additional","affiliation":[{"name":"Immunology and Pharmacology Department, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, Allschwil , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Tunis","sequence":"additional","affiliation":[{"name":"Immunology and Pharmacology Department, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, Allschwil , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sassi","sequence":"additional","affiliation":[{"name":"Immunology and Pharmacology Department, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, Allschwil , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Tondello","sequence":"additional","affiliation":[{"name":"Pharmazentrum Frankfurt, Goethe University Frankfurt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Bayer","sequence":"additional","affiliation":[{"name":"Pharmazentrum Frankfurt, Goethe University Frankfurt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Hintermann","sequence":"additional","affiliation":[{"name":"Pharmazentrum Frankfurt, Goethe University Frankfurt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S","family":"Strasser","sequence":"additional","affiliation":[{"name":"Translational Biomarkers Department, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, Allschwil , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Schuldes","sequence":"additional","affiliation":[{"name":"Project Management Department, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, Allschwil , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mentzel","sequence":"additional","affiliation":[{"name":"Pharmacology and Preclinical Development Department, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, Allschwil , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-3423","authenticated-orcid":false,"given":"Marianne M","family":"Martinic","sequence":"additional","affiliation":[{"name":"Immunology and Pharmacology Department, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, Allschwil , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"2023121223013876400_CIT0001","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"key":"2023121223013876400_CIT0002","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2337\/dc20-0567","article-title":"Clinical impact of residual C-peptide secretion in type 1 diabetes on glycemia and microvascular complications","volume":"44","author":"Jeyam","year":"2021","journal-title":"Diabetes Care"},{"key":"2023121223013876400_CIT0003","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S2213-8587(22)00390-4","article-title":"Teplizumab approval for type 1 diabetes in the USA","volume":"11","author":"Evans-Molina","year":"2023","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"2023121223013876400_CIT0004","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"2023121223013876400_CIT0005","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci Transl Med"},{"key":"2023121223013876400_CIT0006","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-023-01847-y","article-title":"Teplizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"2023121223013876400_CIT0007","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N Engl J Med"},{"key":"2023121223013876400_CIT0008","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","article-title":"A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes","volume":"54","author":"Herold","year":"2005","journal-title":"Diabetes"},{"key":"2023121223013876400_CIT0009","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders","volume":"62","author":"Herold","year":"2013","journal-title":"Diabetes"},{"key":"2023121223013876400_CIT0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1073\/pnas.91.1.123","article-title":"Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice","volume":"91","author":"Chatenoud","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023121223013876400_CIT0011","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nri2134","article-title":"CD3-specific antibodies: a portal to the treatment of autoimmunity","volume":"7","author":"Chatenoud","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"2023121223013876400_CIT0012","doi-asserted-by":"crossref","first-page":"eaai7793","DOI":"10.1126\/sciimmunol.aai7793","article-title":"Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes","volume":"1","author":"Long","year":"2016","journal-title":"Sci Immunol"},{"key":"2023121223013876400_CIT0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cellimm.2017.07.007","article-title":"Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes","volume":"319","author":"Long","year":"2017","journal-title":"Cell Immunol"},{"key":"2023121223013876400_CIT0014","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/eji.201545708","article-title":"Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes","volume":"46","author":"Tooley","year":"2016","journal-title":"Eur J Immunol"},{"key":"2023121223013876400_CIT0015","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00125-018-4786-9","article-title":"Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis","volume":"62","author":"Perdigoto","year":"2019","journal-title":"Diabetologia"},{"key":"2023121223013876400_CIT0016","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fendo.2020.606434","article-title":"New insights into the role of autoreactive CD8 T cells and cytokines in human type 1 diabetes","volume":"11","author":"Bender","year":"2021","journal-title":"Front Endocrinol"},{"key":"2023121223013876400_CIT0017","first-page":"83","article-title":"Chemokines as drivers of the autoimmune destruction in type 1 diabetes: opportunity for therapeutic intervention in consideration of an optimal treatment schedule","volume":"11","author":"Christen","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2023121223013876400_CIT0018","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2337\/db16-0547","article-title":"Islet-Expressed CXCL10 promotes autoimmune destruction of islet isografts in mice with type 1 diabetes","volume":"66","author":"Bender","year":"2017","journal-title":"Diabetes"},{"key":"2023121223013876400_CIT0019","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1084\/jem.20111187","article-title":"Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients","volume":"209","author":"Coppieters","year":"2012","journal-title":"J Exp Med"},{"key":"2023121223013876400_CIT0020","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2337\/db09-0091","article-title":"Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes","volume":"58","author":"Tanaka","year":"2009","journal-title":"Diabetes"},{"key":"2023121223013876400_CIT0021","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1507\/endocrj.K10E-076","article-title":"Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes","volume":"57","author":"Uno","year":"2010","journal-title":"Endocr J"},{"key":"2023121223013876400_CIT0022","first-page":"3390","article-title":"CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope","volume":"118","author":"Skowera","year":"2008","journal-title":"J Clin Invest"},{"key":"2023121223013876400_CIT0023","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2249.2009.04087.x","article-title":"Islet inflammation and CXCL10 in recent-onset type 1 diabetes","volume":"159","author":"Roep","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"2023121223013876400_CIT0024","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/nm1202-792","article-title":"\u03b2 cells are responsible for CXCR3-mediated T-cell infiltration in insulitis","volume":"8","author":"Frigerio","year":"2002","journal-title":"Nat Med"},{"key":"2023121223013876400_CIT0025","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.2337\/db12-1370","article-title":"Functional redundancy of CXCR3\/CXCL10 signaling in the recruitment of diabetogenic cytotoxic T lymphocytes to pancreatic islets in a virally induced autoimmune diabetes model","volume":"62","author":"Coppieters","year":"2013","journal-title":"Diabetes"},{"key":"2023121223013876400_CIT0026","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2249.2011.04426.x","article-title":"Small molecule CXCR3 antagonist NIBR2130 has only a limited impact on type 1 diabetes in a virus-induced mouse model","volume":"165","author":"Christen","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"2023121223013876400_CIT0027","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.2337\/db15-0479","article-title":"Anti-CD3\/Anti-CXCL10 antibody combination therapy induces a persistent remission of type 1 diabetes in two mouse models","volume":"64","author":"Lasch","year":"2015","journal-title":"Diabetes"},{"key":"2023121223013876400_CIT0028","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170767","article-title":"Human immune phenotyping reveals accelerated aging in type 1 diabetes","author":"Shapiro","year":"2023"},{"key":"2023121223013876400_CIT0029","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1021\/acs.jmedchem.3c00074","article-title":"Discovery of Clinical Candidate ACT-777991, a potent CXCR3 antagonist for antigen-driven and inflammatory pathologies","volume":"66","author":"Meyer","year":"2023","journal-title":"J Med Chem"},{"key":"2023121223013876400_CIT0030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0092-8674(91)90165-U","article-title":"Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response","volume":"65","author":"Oldstone","year":"1991","journal-title":"Cell"},{"key":"2023121223013876400_CIT0031","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0092-8674(91)90164-T","article-title":"Ablation of \u201ctolerance\u201d and induction of diabetes by virus infection in viral antigen transgenic mice","volume":"65","author":"Ohashi","year":"1991","journal-title":"Cell"},{"key":"2023121223013876400_CIT0032","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev.immunol.23.021704.115643","article-title":"THE NOD MOUSE: a model of immune dysregulation","volume":"23","author":"Anderson","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"2023121223013876400_CIT0033","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/1074-7613(94)90101-5","article-title":"How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model","volume":"1","author":"von Herrath","year":"1994","journal-title":"Immunity"},{"key":"2023121223013876400_CIT0034","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"2023121223013876400_CIT0035","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1073\/pnas.1101881108","article-title":"Expression of chemokine receptor CXCR3 on T cells affects the balance between effector and memory CD8 T-cell generation","volume":"108","author":"Hu","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023121223013876400_CIT0036","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","article-title":"CXCR3 in T cell function","volume":"317","author":"Groom","year":"2011","journal-title":"Exp Cell Res"},{"key":"2023121223013876400_CIT0037","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(18)31506-X","article-title":"Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study","volume":"392","author":"Rawshani","year":"2018","journal-title":"The Lancet"},{"key":"2023121223013876400_CIT0038","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.4049\/jimmunol.171.12.6838","article-title":"Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease","volume":"171","author":"Christen","year":"2003","journal-title":"J Immunol"},{"key":"2023121223013876400_CIT0039","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s00125-018-4651-x","article-title":"Loss of CXCR3 expression on memory B cells in individuals with long-standing type 1 diabetes","volume":"61","author":"Powell","year":"2018","journal-title":"Diabetologia"},{"key":"2023121223013876400_CIT0040","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.4049\/jimmunol.175.6.3516","article-title":"Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development","volume":"175","author":"Rhode","year":"2005","journal-title":"J Immunol"},{"key":"2023121223013876400_CIT0041","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41586-021-04248-x","article-title":"An autoimmune stem-like CD8 T cell population drives type 1 diabetes","volume":"602","author":"Gearty","year":"2022","journal-title":"Nature"},{"key":"2023121223013876400_CIT0042","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.immuni.2015.02.009","article-title":"CXCR3 chemokine receptor enables local CD8(+) T cell migration for the destruction of virus-infected cells","volume":"42","author":"Hickman","year":"2015","journal-title":"Immunity"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxad083\/51013534\/uxad083.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/214\/2\/131\/54329564\/uxad083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/214\/2\/131\/54329564\/uxad083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T23:03:22Z","timestamp":1702422202000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/214\/2\/131\/7225150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,7,17]]},"published-print":{"date-parts":[[2023,12,12]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxad083","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,7,17]]}}}